Benoit Aguado, Grégoire Ruffenach, Thomas Lacoste-Palasset, Agnes Görlach, Marianne Riou, Mathieu Gourmelon, Fabrice Bauer, Marc Humbert, Valerie Schini-Kerth, Jean-Luc Vachiéry, David Montani, Fabrice Antigny
Université Paris-Saclay and French National Institute for Health and Medical Research. Hôpital Bicêtre and Hôpital Marie Lannelongue. Technical University Munich and German Centre for Cardiovascular Research. Nouvel Hôpital Civil and University Hospital of Strasbourg. Cliniques Universitaires de Bruxelles-Hôpital Erasme.
France, Germany and Belgium
Circulation Heart Failure
Circ Heart Fail 2025;
DOI: 10.1161/CIRCHEARTFAILURE.125.013481
Abstract
Inhibiting SGLT2 (sodium-glucose cotransporter 2) has recently transformed the medical care of patients with left heart disease. Right ventricular failure is a major predictor for patients suffering from pulmonary hypertension of various causes, including those with postcapillary pulmonary hypertension due to left heart disease. Similar to how SGLT2 inhibition benefits patients with left heart failure, recent studies have suggested utilizing these molecules to enhance right ventricular function in pulmonary hypertension. In this review, we summarize the current knowledge on the use of SGLT2is (SGLT2 inhibitors) in pulmonary hypertension. Further dedicated trials are necessary to establish their role in right ventricular pulmonary vascular disease.
Category
Class II. Pulmonary Hypertension Associated with Left Ventricular Systolic or Diastolic Dysfunction
Heart Dysfunction Associated with Pulmonary Vascular Disease (Right and Left)
Medical Therapy. Efficacy or Lack of Efficacy
Review Articles Concerning Pulmonary Vascular Disease
Age Focus: Pediatric Pulmonary Vascular Disease or Adult Pulmonary Vascular Disease
Fresh or Filed Publication: Fresh (PHresh). Less than 1-2 years since publication
Article Access
Free PDF File or Full Text Article Available Through PubMed or DOI: Yes